More than one in five patients with well-controlled diabetes were receiving more medications than recommended, many of them elderly or with multiple comorbidities, a recent study found.
Sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists had similar rates of other adverse events, including bone fracture, acute kidney injury, serious urinary tract infection, venous thromboembolism, and
Age, sex, body mass index, peripheral sensory neuropathy, and estimated glomerular filtration rate were the included variables.
The results highlight the potential benefit of targeting individuals with an elevated one-hour blood glucose level and, if supported by additional evidence, eventually replacing the two-hour test with a ... Our results highlight the potential benefit of
The findings may reassure prescribers of dipeptidyl peptidase-4 inhibitors that the drug class does not significantly increase the risk of adverse pancreatic outcomes compared with other second-line therapies, study authors said.
The studied risk factors were HbA1c level, LDL cholesterol level, presence of albuminuria, smoking status, and blood pressure.
A study conducted in Australia found that general practitioners with specialization in diabetes care and subspecialist-led clinics reduced HbA1c levels by similar amounts in patients with complex type 2 diabetes.
The findings underscore the urgency of early diagnosis of diabetes and the consequences of failing to achieve near-normal glycemia soon after patients are diagnosed, according to the study authors.
In a retrospective observational study, patients with prediabetes were assigned to a risk category for diabetes based on presence and severity of insulin resistance, impaired beta-cell function, and hyperglycemia, then treated accordingly.
Among patients with coronary artery disease, severity and frequency of hypoglycemia were associated with increased levels of high-sensitivity cardiac troponin T, although the association was attenuated in adjusted analyses.